TLDR:
- InflaRx stock up 2.5% ahead of Phase 2a data release.
- Phase 2a trial results for INF904 expected November 10, 2025.
- InflaRx to report Q3 2025 financial results alongside clinical data.
- INF904 shows promise as oral therapy for chronic inflammatory diseases.
- InflaRx’s focus on C5a inhibition could transform anti-inflammatory treatments.
Inflarx N.V. (IFRX) saw a 2.5% increase in its stock price, closing at $1.23.
InflaRx N.V., IFRX
The rise comes just ahead of the company’s highly anticipated Phase 2a clinical trial data release. The data is expected to be revealed on Monday, November 10, 2025, in a pre-market press release. Investors are awaiting topline results from the trial, which evaluates the oral C5aR inhibitor INF904 in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU).
Key Data Announcement Set for November 10, 2025
InflaRx will report topline data from its Phase 2a clinical trial of INF904. The trial focuses on patients with hidradenitis suppurativa and chronic spontaneous urticaria. The company plans to disclose the findings in a pre-market press release on November 10, 2025. The release will include detailed information on the performance of INF904, an oral small molecule inhibitor of C5a-induced signaling via the C5a receptor.
The trial aims to assess INF904’s effectiveness in reducing inflammation for these conditions. Both HS and CSU are chronic inflammatory diseases with limited treatment options. InflaRx’s focus on complement system inhibition has positioned the company as a potential leader in anti-inflammatory therapeutics.
Alongside the topline data, InflaRx will host a webcast and conference call. The event is scheduled for 8:00 AM EST / 2:00 PM CET. The webcast will feature insights from key opinion leaders, providing further context to the data and its implications for treatment options.
Company to Release Q3 2025 Financial Results Alongside Clinical Data
In addition to the clinical data release, InflaRx will report its third-quarter 2025 financial results. The financial update will be published through a Form 6-K, also on November 10, 2025, before the market opens. The quarterly results will provide an overview of the company’s financial standing, including revenue, expenses, and operational progress.
This financial release will be closely scrutinized for any updates on the company’s ongoing clinical programs. Investors will likely look for signs of progress in the commercialization of InflaRx’s therapies, particularly vilobelimab, the company’s first-in-class anti-C5a monoclonal antibody. This antibody has already demonstrated positive results in multiple clinical trials.
INF904, the drug under evaluation in the Phase 2a trial, represents an important step in InflaRx’s development pipeline. As an oral therapy, INF904 offers a potentially more convenient option compared to the company’s intravenous treatments. These advancements highlight the company’s commitment to expanding its portfolio of anti-inflammatory therapeutics.
About InflaRx N.V. and Its Pipeline
InflaRx N.V. specializes in developing anti-inflammatory drugs targeting the complement system. The company’s main focus is on the complement activation factor C5a and its receptor, C5aR. C5a is a potent mediator of inflammation involved in various chronic diseases.
InflaRx’s lead drug, vilobelimab, is a monoclonal antibody that has demonstrated effectiveness in treating diseases like hidradenitis suppurativa. The company is also progressing with INF904, an oral small molecule inhibitor of C5a-induced signaling. This innovative approach could offer a new therapeutic option for patients suffering from inflammatory conditions like HS and CSU.
As InflaRx advances its clinical trials and prepares for future commercial opportunities, the upcoming Phase 2a results may serve as a critical milestone. The data release could play a key role in shaping the company’s strategic direction and market positioning in the biopharmaceutical industry.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
